valproic acid has been researched along with Brain Disorders in 126 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Valproic acid (VPA) is an FDA-approved medication widely prescribed for seizures, migraines, and mixed or manic episodes in bipolar disorder." | 7.85 | Reversible Encephalopathy due to Valproic Acid Induced Hyperammonemia in a Patient with Bipolar I Disorder: A Cautionary Report. ( Birur, B; Fargason, RE; Landry, KB; Patel, N, 2017) |
| " However, he was found to have hyperammonemia within 2 weeks after the addition of low-dose topiramate to valproate." | 7.73 | Topiramate-valproate-induced hyperammonemic encephalopathy syndrome: case report. ( Cheung, E; Fung, CW; Wong, V, 2005) |
| "A 15-year-old boy with epilepsy and cerebral calcifications, treated with valproic acid, ethyl phenylbarbiturate and ethosuximide, was referred for drug induced systemic lupus erythematosus." | 7.71 | Latent coeliac disease in a child with epilepsy, cerebral calcifications, drug-induced systemic lupus erythematosus and intestinal folic acid malabsorption associated with impairment of folic acid transport across the blood-brain barrier. ( Calvani, M; Guaitolini, C; Paolone, G; Parisi, G; Parisi, P, 2001) |
| "In an asphyxial cardiac arrest rat model, administration of VPA improved neurologic outcomes and added a neuroprotective effect to HT." | 5.42 | Effect of valproic acid combined with therapeutic hypothermia on neurologic outcome in asphyxial cardiac arrest model of rats. ( Hwang, JE; Jo, YH; Kim, K; Kim, MA; Lee, JH; Lee, MJ, 2015) |
| "The survival rates at 72h after cardiac arrest were significantly higher in VPA group than in control group (6/8 in VPA group, 3/10 rats in control group; log rank test, p<0." | 5.39 | Effect of valproic acid on survival and neurologic outcomes in an asphyxial cardiac arrest model of rats. ( Jo, YH; Kang, C; Kim, J; Kim, K; Kim, MA; Lee, JH; Lee, MJ; Lee, SH; Park, CJ; Rhee, JE, 2013) |
| "Under the medicine treatment of magnesium valproate with carbamazepine, the patient experienced partial seizures approximately once per month that lasted 30 to 60 seconds each without any complications observed during a follow-up period of 24 months." | 5.01 | A potential cause of adolescent onset Dyke-Davidoff-Masson syndrome: A case report. ( Jiang, Z; Li, B; Li, J; Li, Y; Wang, L; Zhang, T, 2019) |
| "Valproic acid is an effective mood stabilizer, registered for the treatment of bipolar disorder and epilepsy." | 4.31 | [A severe, reversible encephalopathy after prolonged use of valproic acid]. ( Bloemkolk, D; Gerritse, FL; Rundervoort, RS; van Haaren, PCF, 2023) |
| "We present a case of a 29-year-old female with a history of epilepsy who was admitted for convulsive status epilepticus (CSE), which was controlled by intravenous VPA, as well as oral VPA and phenytoin." | 4.31 | Valproate-related hyperammonemic encephalopathy with generalized suppression EEG: a case report. ( Liu, X; Peng, X, 2023) |
| "Valproic acid (VPA) is an FDA-approved medication widely prescribed for seizures, migraines, and mixed or manic episodes in bipolar disorder." | 3.85 | Reversible Encephalopathy due to Valproic Acid Induced Hyperammonemia in a Patient with Bipolar I Disorder: A Cautionary Report. ( Birur, B; Fargason, RE; Landry, KB; Patel, N, 2017) |
| "This 13-year-old girl with autism and intractable epilepsy experienced increased seizures; her valproic acid dose was increased and other antiepileptic drugs were administered." | 3.85 | Burst Suppression Pattern on Electroencephalogram Secondary to Valproic Acid-Induced Hyperammonemic Encephalopathy. ( Cherian, KA; Legatt, AD, 2017) |
| " He was found to have high anion gap metabolic acidosis with significantly elevated lactate along with an elevated osmolal gap and calcium oxalate crystals in his urine." | 3.85 | Two gaps too many, three clues too few? Do elevated osmolal and anion gaps with crystalluria always mean ethylene glycol poisoning? ( Abu Sitta, E; Gaddam, M; Kanzy, A; Velagapudi, RK, 2017) |
| "We report the case of an aborted awake craniotomy for a left frontotemporoinsular glioma due to ammonia encephalopathy on a patient taking Levetiracetam, valproic acid and clobazam." | 3.81 | Ammonia encephalopathy and awake craniotomy for brain language mapping: cause of failed awake craniotomy. ( Arroyo Pérez, R; Fernández-Candil, JL; León Jorba, A; Pacreu Terradas, S; Villalba Martínez, G; Vivanco-Hidalgo, RM, 2015) |
| " Ten patients on valproic acid therapy of any age group with idiopathic or secondary epilepsy, who presented with encephalopathic symptoms, were registered and followed up during the study." | 3.79 | Valproic acid induced hyperammonaemic encephalopathy. ( Amanat, S; Hassan, Y; Shahbaz, N, 2013) |
| " We investigated for the first time whether class I histone deacetylase inhibitor valproic acid (VPA) can reverse cognitive deficits in a mouse model of sepsis-associated encephalopathy (SAE)." | 3.79 | Class I histone deacetylase inhibitor valproic acid reverses cognitive deficits in a mouse model of septic encephalopathy. ( Dong, L; Ji, M; Jia, M; Qiu, L; Wu, J; Yang, J; Zhang, G; Zhang, M, 2013) |
| " However, he was found to have hyperammonemia within 2 weeks after the addition of low-dose topiramate to valproate." | 3.73 | Topiramate-valproate-induced hyperammonemic encephalopathy syndrome: case report. ( Cheung, E; Fung, CW; Wong, V, 2005) |
| "Serum or CSF glutamine levels are initially elevated in a majority of patients with suspected VHE, sometimes in the absence of hyperammonemia." | 3.71 | Serum and CSF glutamine levels in valproate-related hyperammonemic encephalopathy. ( Cawthon, DF; Caylor, LM; Kraemer, DL; Morgan, JD; Ojemann, LM; Vossler, DG; Wilensky, AJ, 2002) |
| "A 15-year-old boy with epilepsy and cerebral calcifications, treated with valproic acid, ethyl phenylbarbiturate and ethosuximide, was referred for drug induced systemic lupus erythematosus." | 3.71 | Latent coeliac disease in a child with epilepsy, cerebral calcifications, drug-induced systemic lupus erythematosus and intestinal folic acid malabsorption associated with impairment of folic acid transport across the blood-brain barrier. ( Calvani, M; Guaitolini, C; Paolone, G; Parisi, G; Parisi, P, 2001) |
| "Two adult patients with focal epilepsy who tolerated valproate (VPA) well in different combinations of anticonvulsants developed hyperammonemic encephalopathy when treated with VPA in combination with topiramate (TPM)." | 3.70 | Valproate-induced hyperammonemic encephalopathy in the presence of topiramate. ( Hamer, HM; Knake, S; Rosenow, F; Schomburg, U, 2000) |
| "A 24-years-old woman with epilepsy treated with valproic acid developed disorientation, acalculia, perseveration, slow responsiveness and loss of memory." | 3.70 | [A case report of valproate encephalopathy]. ( Hirata, K; Katayama, S; Miyamoto, M; Miyamoto, T, 1999) |
| "To determine an optimal biologic dose (OBD) of decitabine as a single agent and then the maximum-tolerated dose (MTD) of valproic acid (VA) combined with decitabine in acute myeloid leukemia (AML)." | 2.73 | Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. ( Blum, W; Byrd, JC; Chan, KK; Devine, H; Devine, SM; Grever, MR; Hackanson, B; Heerema, NA; Huynh, L; Kefauver, C; Klisovic, RB; Liu, S; Liu, Z; Lozanski, G; Marcucci, G; Murgo, A; Plass, C; Vukosavljevic, T, 2007) |
| "Valproic acid-induced encephalopathy mainly manifests as acute or subacute encephalopathy and has been associated with hyperammonemia, L-carnitine deficiency, and urea cycle enzyme dysfunction." | 2.72 | Valproic acid-induced encephalopathy: A review of clinical features, risk factors, diagnosis, and treatment. ( Jing, W; Li, J; Tian, X; Wang, X; Wu, J, 2021) |
| "Minimal requirements: seizure-prevention outcome given as fraction of cases; AED or control assigned by random or quasi-random mechanism." | 2.41 | Antiepileptogenesis and seizure prevention trials with antiepileptic drugs: meta-analysis of controlled trials. ( Temkin, NR, 2001) |
| "Valproic acid (VPA) is an effective anticonvulsant useful in many types of epilepsy and, although it is usually well tolerated, it has been associated with many neurological and systemic side effects." | 2.41 | Valproate-induced hyperammonemic encephalopathy. ( Chiarelli, F; Morgese, G; Trotta, D; Verrotti, A, 2002) |
| "Susac syndrome is an occlusive arteriolar disease that provokes infarcts in the cochlea, retina, and brain of young subjects, mostly women." | 2.40 | Susac syndrome. ( Aumaitre, O; Biousse, V; Bousser, MG; Fardeau, C; Godeau, P; Huong, DL; Lehoang, P; N'Guyen, N; Papo, T; Piette, JC, 1998) |
| "The patient developed hyperammonaemic encephalopathy due to sodium valproate overdose and was treated with supportive care and renal replacement therapy." | 1.91 | Valproate overdose leading to hyperammonaemic encephalopathy. ( Gupta, S; Sharma, DS; Sharma, P, 2023) |
| "Valproate-induced encephalopathy (VIE) affects between 0." | 1.91 | Acute Valproate-Induced Encephalopathy in Status Epilepticus: A Registry-Based Assessment. ( Beuchat, I; Loser, V; Novy, J; Rossetti, AO, 2023) |
| "This is a type of VPA-related encephalopathy, different from dose-dependent toxic encephalopathy, hyperammonaemic encephalopathy or encephalopathy related to liver failure." | 1.91 | Cerebral and cerebellar pseudoatrophy associated with valproic acid. Report of three pediatric cases. ( Arias-Vivas, E; Duat-Rodríguez, A; García-Peñas, JJ; González-Alguacil, E; Gutiérrez-Delicado, E; Heppe-Montero, M; Justel-Rodríguez, M; Ordoño-Saiz, MV; Púa-Torrejón, RC; Ruiz-Falcó-Rojas, ML; Soto-Insuga, V, 2023) |
| "Levocarnitine is the treatment of choice in valproic acid toxicity-related hyperammonaemia." | 1.62 | Managing valproic acid toxicity-related hyperammonaemia: an unpredicted course. ( Edquist, C; O'Rourke, N; Pagali, S, 2021) |
| "Hyperammonemic encephalopathy is a rare and serious adverse reaction to valproate." | 1.56 | Valproate-induced hyperammonemic encephalopathy: a case report. ( Shah, S; Vieux, U; Wang, R, 2020) |
| "Hyperammonemic encephalopathy secondary to the use of valproate is rare without evidence of hepatotoxicity, and it usually presents with confusion, agitation, irritability, cognitive disturbances, lethargy, coma, and death." | 1.48 | Valproate-induced Hyperammonemic Encephalopathy Presenting as Catatonia. ( Espínola-Nadurille, M; Oñate-Cadena, N; Pérez-Esparza, R; Ramírez-Bermúdez, J, 2018) |
| "In an asphyxial cardiac arrest rat model, administration of VPA improved neurologic outcomes and added a neuroprotective effect to HT." | 1.42 | Effect of valproic acid combined with therapeutic hypothermia on neurologic outcome in asphyxial cardiac arrest model of rats. ( Hwang, JE; Jo, YH; Kim, K; Kim, MA; Lee, JH; Lee, MJ, 2015) |
| "VPA-induced encephalopathy is an uncommon but serious adverse effect that should be considered in patients with cognitive decline during VPA treatment." | 1.42 | [Valproate can induce reversible encephalopathy]. ( Christensen, J; Harbo, T; Prakash, S, 2015) |
| "Carnitine supplement was administrated in two patients, which resulted in resolution of symptoms and normalized ammonium levels." | 1.40 | Valproate-induced hyperammonemia in juvenile ceroid lipofuscinosis (Batten disease). ( Larsen, EP; Ostergaard, JR, 2014) |
| "Valproate-induced hyperammonemic encephalopathy is an uncommon but serious effect of valproate treatment." | 1.40 | Valproate-induced hyperammonemic encephalopathy in a renal transplanted patient. ( Boletis, JN; Darema, M; Efthimiou, A; Marinaki, S; Melexopoulou, C; Skalioti, C; Zavos, G, 2014) |
| "Valproate (VPA)-induced encephalopathy is a rare but serious complication, presenting with impaired consciousness, with or without hyperammonemia, normal liver enzymes, and normal serum level of VPA." | 1.40 | Valproate-related erythrodermia with reversible encephalopathy: a rare but serious adverse reaction, case report. ( Balkovec, V; Rener-Primec, Z, 2014) |
| "VPA-induced encephalopathy is an uncommon but serious adverse effect that should be considered in patients with cognitive decline during VPA treatment." | 1.40 | [Valproate can induce reversible encephalopathy]. ( Christensen, J; Harbo, T; Prakash, S, 2014) |
| " The symptoms of VHE were not correlated with the dosage and concentration of valproate." | 1.40 | [Clinical misdiagnosis analysis of valproate encephalopathy]. ( Chen, X; Su, Z; Wu, Z; Ye, S; Zhu, D; Zhuge, G, 2014) |
| "The survival rates at 72h after cardiac arrest were significantly higher in VPA group than in control group (6/8 in VPA group, 3/10 rats in control group; log rank test, p<0." | 1.39 | Effect of valproic acid on survival and neurologic outcomes in an asphyxial cardiac arrest model of rats. ( Jo, YH; Kang, C; Kim, J; Kim, K; Kim, MA; Lee, JH; Lee, MJ; Lee, SH; Park, CJ; Rhee, JE, 2013) |
| "Metabolic encephalopathy is a rare but serious complication of valproic acid (VPA) therapy that usually presents with impaired consciousness or increased seizure frequency." | 1.39 | Topiramate increases the risk of valproic acid-induced encephalopathy. ( Chu, K; Jung, KH; Kim, DW; Lee, SK; Lee, ST; Moon, HJ; Noh, Y, 2013) |
| "Subacute encephalopathy with seizures in chronic alcoholism (SESA) was first described in 1981 by Niedermeyer who reported alcoholic patients presenting with confusion, seizures and focal neurological deficits and is quite distinct from patients presenting with typical alcohol withdrawal seizures." | 1.37 | Subacute encephalopathy and seizures in alcoholics (SESA) presenting with non-convulsive status epilepticus. ( LaRoche, SM; Shivdat-Nanhoe, R, 2011) |
| "Valproate-induced hyperammonemic encephalopathy is an unusual but serious complication that may occur in people with normal liver-associated enzyme levels, despite normal therapeutic doses and serum levels of valproate." | 1.35 | Valproate-induced hyperammonemic encephalopathy treated by hemodialysis. ( Chen, CY; Tsai, MF, 2008) |
| " The steady-state plasma concentrations of AEDs at the experimental dosage were coincided with the range of clinical therapeutic concentrations." | 1.34 | [Experimental study on the possibility of brain damage induced by chronic treatment with phenobarbital, clonazepam, valproic acid and topiramate in immature rats]. ( Cai, FC; Zhang, XP; Zhu, HX, 2007) |
| "This drug-associated encephalopathy is a reversible but potentially fatal cause, probably underdiagnosed, that requires a high index of suspicion." | 1.34 | [Valproate-associated hyperammonemic encephalopathy. Report of one case]. ( Alvarez, F; Bruetman, JE; Finn, BC; Trimarchi, H; Young, P, 2007) |
| "An important subset of children with nonketotic hyperglycinemia are atypical variants who present in a heterogeneous manner." | 1.33 | Valproate-induced chorea and encephalopathy in atypical nonketotic hyperglycinemia. ( Morrison, PF; Sankar, R; Shields, WD, 2006) |
| "Valproic acid (VPA) is a broad-spectrum antiepileptic drug and is usually well-tolerated." | 1.33 | Valproic acid induced encephalopathy--19 new cases in Germany from 1994 to 2003--a side effect associated to VPA-therapy not only in young children. ( Augspach-Hofmann, R; Bendl, C; Buesing, D; Fitzek, S; Gerstner, T; Goetze, G; Haensch, CA; Klostermann, W; Koenig, SA; Lippert, G; Longin, E; Macke, A; Mayer, G; Reuland, M; Scheid, B; Wenzel, D, 2006) |
| "Valproate-induced encephalopathy is a rare syndrome that may manifest in otherwise normal epileptic individuals." | 1.33 | Valproate-induced encephalopathy. ( Rehman, A; Zafar, S, 2005) |
| "Valproic acid-associated hyperammonemic encephalopathy (VHE) has been described in the neurology and emergency medicine literature, but the case reports identified therein are rarely derived from the psychiatric use of this medication." | 1.33 | Valproic acid-associated hyperammonemic encephalopathy: a case report from the psychiatric setting. ( Irwin, SA; Kimmel, RJ; Meyer, JM, 2005) |
| "By doing so, he developed myoclonus, tremor and encephalopathy with sedation and marked EEG background slowing." | 1.32 | Encephalopathy and myoclonus triggered by valproic acid. ( Fallgatter, AJ; Leonhard, C; Lesch, KP; Mössner, R; Reif, A, 2004) |
| "VPA-induced hyperammonemic encephalopathy in adults is a rare phenomenon, especially when VPA is used as monotherapy." | 1.32 | Hyperammonemic encephalopathy induced by a combination of valproate and pivmecillinam. ( Asztely, F; Eriksson, B; Lokrantz, CM; Rosén, I, 2004) |
| "The aim of the study was to analyse the astrocyte ultrastructure within the hippocampal gyre cortex and neocortex of the temporal lobe in valproate encephalopathy induced by chronic administration of an anti-epileptic drug - sodium valproate (VPA) to rats for 1, 3, 6, 9 and 12 months, once daily intragastrically, in a dose of 200 mg/kg b." | 1.32 | Ultrastructure of astrocytes in the cortex of the hippocampal gyrus and in the neocortex of the temporal lobe in experimental valproate encephalopathy and after valproate withdrawal. ( Sobaniec-Lotowska, ME, 2003) |
| " A relatively large initial VPA dosage could possibly be the culprit." | 1.31 | Valproate-induced encephalopathy. ( Chen, WT; Liao, KK; Yen, DJ; Yu, HY, 2001) |
| " One month after terminating of chronic administration this value was close to the one found after 12 months of the study." | 1.31 | Morphometric analysis of the cerebellar cortex capillaries in the course of experimental valproate encephalopathy and after chronic exposure to sodium valproate using transmission electron microscopy. ( Augustynowicz, A; Sobaniec, W; Sobaniec-Lotowska, M, 2001) |
| " Reduction of VPA dosage and subsequent discontinuation 4 months later resulted in disappearance of clinical symptoms with a 20-point improvement at IQ testing and recovery of previous PM score." | 1.30 | Reversible pseudoatrophy of the brain and mental deterioration associated with valproate treatment. ( Belmonte, A; Canapicchi, R; Casalini, C; Guerrini, R; Perucca, E, 1998) |
| "We treated a 31-year-old woman with systemic lupus erythematosus, renal failure with nephrotic syndrome, and a long-standing seizure disorder, who developed severe hyperammonemia with a fatal outcome." | 1.30 | Fatal hyperammonemia in a patient with systemic lupus erythematosus. ( Amano, T; Ichikawa, H; Kawabata, K; Kushiro, M; Makino, H; Nagake, Y; Wada, J, 1998) |
| "Valproic acid (VPA)-induced encephalopathy is a rarely considered side effect, with somnolence, reduced motor activity and severe deterioration of cognitive and behavioural abilities." | 1.30 | [Encephalopathies caused by valproate]. ( Bräunig, P; Göbel, R; Görtzen, A, 1999) |
| " In this context, anticonvulsant and neurotoxic pharmacodynamic interactions between phenytoin (PHT) and valproate (VPA) were assessed in an experimental model in mice." | 1.29 | Pharmacodynamic interactions between phenytoin and valproate: individual and combined antiepileptic and neurotoxic actions in mice. ( Bourgeois, BF; Chez, MG; Knowles, WD; Pippenger, CE, 1994) |
| "A 3-year-old boy with West syndrome who was shown to have a cystic lesion on magnetic resonance imagings underwent surgical treatment." | 1.29 | West syndrome associated with porencephaly. ( Aihara, N; Ishikawa, T; Kamiya, K; Kanayama, M; Katano, H; Nagai, H; Yamashita, N, 1994) |
| "Macro square wave jerks and pendular nystagmus were mildly suppressed after the intramuscular injection of 100 mg of phenobarbital, the oral intake of sodium valproate of 600 mg/day or baclofen of 60 mg/day." | 1.28 | [Multiple system atrophy with macro square wave jerks and pendular nystagmus]. ( Fukusako, T; Morimatsu, M; Nogaki, H; Yamamoto, K, 1992) |
| "We describe the case of a 26 years old woman in chronic therapy with phenobarbital, carbamazepine, valproic acid (VPA) and clonazepam who showed a hyperammonemic encephalopathy after an increase in dosage of VPA." | 1.28 | State of stupor from valproic acid during chronic treatment: case report. ( Buffa, C; Gentile, S; Ravetti, C; Sacerdote, I, 1991) |
| "Neurocysticercosis has not to our knowledge been previously reported to have presented with myoclonus." | 1.28 | Myoclonus: a manifestation of neurocysticercosis. ( Chowdhury, V; Gulati, P; Puri, V, 1991) |
| "5 of these patients developed toxic encephalopathy with hyperammonemia induced by VPA." | 1.27 | Treatment of epileptic patients with valproic acid does not modify plasma and urine short-chain-fatty acids. ( Arnetoli, G; Boncinelli, L; Campostrini, R; Paganini, M; Zaccara, G; Zappoli, R, 1983) |
| "Thus, the seizure-facilitating nigral efferents may be subject to inhibition by both GABA and opiates and may normally be driven by substance P." | 1.27 | Role of the substantia nigra in GABA-mediated anticonvulsant actions. ( Gale, K, 1986) |
| "The patients all had frequent clinical seizures and generalized spike-wave discharges." | 1.26 | Sodium valproate: serial monitoring of EEG and serum levels. ( Binnie, CD; de Beer-Pawlikowski, NK; Goedhart, DM; Gutter, T; Meijer, JW; Meinardi, H; Rowan, AJ; van der Geest, P, 1979) |
| " The signs and symptoms did not directly correlate with VPA dosage and the arterial ammonium levels did not correlate with serum VPA concentrations." | 1.26 | Sodium valproate-induced hyperammonemia without clinical hepatic dysfunction. ( Beckner, RR; Marini, AM; Passarelli, C; Wagle, W; Zaret, BS, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 16 (12.70) | 18.7374 |
| 1990's | 23 (18.25) | 18.2507 |
| 2000's | 29 (23.02) | 29.6817 |
| 2010's | 38 (30.16) | 24.3611 |
| 2020's | 20 (15.87) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, L | 1 |
| Xu, Z | 1 |
| Huang, H | 1 |
| Anthonipillai, P | 1 |
| Sharp, G | 1 |
| Kimber, J | 1 |
| Ziauddin, V | 1 |
| Chetwood, JD | 1 |
| Koorey, D | 1 |
| Bryant, C | 1 |
| van Haaren, PCF | 1 |
| Bloemkolk, D | 1 |
| Rundervoort, RS | 1 |
| Gerritse, FL | 1 |
| Yu-E, Y | 1 |
| Zhi-Qin, L | 1 |
| Hui, L | 1 |
| Zheng-Li, D | 1 |
| Fang, Z | 1 |
| Fang, Y | 1 |
| Liu, X | 1 |
| Peng, X | 1 |
| Sharma, DS | 1 |
| Gupta, S | 1 |
| Sharma, P | 1 |
| Loser, V | 1 |
| Novy, J | 1 |
| Beuchat, I | 1 |
| Rossetti, AO | 1 |
| Ordoño-Saiz, MV | 1 |
| Púa-Torrejón, RC | 1 |
| Justel-Rodríguez, M | 1 |
| Arias-Vivas, E | 1 |
| Heppe-Montero, M | 1 |
| González-Alguacil, E | 1 |
| Duat-Rodríguez, A | 1 |
| Ruiz-Falcó-Rojas, ML | 1 |
| García-Peñas, JJ | 1 |
| Gutiérrez-Delicado, E | 1 |
| Soto-Insuga, V | 1 |
| Ranjith, S | 1 |
| Abeysundera, H | 1 |
| Jeyaranjan, H | 1 |
| Baumgartner, J | 1 |
| Hoeflich, A | 1 |
| Hinterbuchinger, B | 1 |
| Fellinger, M | 1 |
| Graf, I | 1 |
| Friedrich, F | 1 |
| Frey, R | 1 |
| Mossaheb, N | 1 |
| Li, Y | 1 |
| Zhang, T | 1 |
| Li, B | 1 |
| Li, J | 2 |
| Wang, L | 1 |
| Jiang, Z | 1 |
| Shah, S | 1 |
| Wang, R | 1 |
| Vieux, U | 1 |
| Lu, PL | 1 |
| Hodes, JF | 1 |
| Zheng, X | 1 |
| Hu, XY | 1 |
| Ilieva, HS | 1 |
| Newman, JW | 1 |
| Fields, RK | 1 |
| Croom, JE | 1 |
| Pei, W | 1 |
| Fu, L | 1 |
| Li, SQ | 1 |
| Yu, Y | 1 |
| Pagali, S | 1 |
| Edquist, C | 1 |
| O'Rourke, N | 1 |
| Wu, J | 2 |
| Jing, W | 1 |
| Tian, X | 1 |
| Wang, X | 1 |
| Kazmierski, D | 1 |
| Sharma, N | 1 |
| O'Leary, K | 1 |
| Ochieng, P | 1 |
| Zhao, K | 1 |
| Lv, D | 1 |
| Chen, M | 1 |
| Yang, Y | 1 |
| Pellegrino, F | 1 |
| Tardivo, I | 1 |
| Cherian, KA | 1 |
| Legatt, AD | 1 |
| Chatterjee, SS | 1 |
| Mitra, S | 1 |
| Das, S | 2 |
| Das, R | 1 |
| Gaddam, M | 1 |
| Velagapudi, RK | 1 |
| Abu Sitta, E | 1 |
| Kanzy, A | 1 |
| Nava-Mateos, JJ | 1 |
| Roiz-Rey, P | 1 |
| Diaz Alvarez-Mediavilla, J | 1 |
| Cebrian-Novella, D | 1 |
| Gomez-Del Olmo, V | 1 |
| Ceberio-Hualde, L | 1 |
| Avila-Cabreja, JA | 1 |
| Fornaris-Cedeno, Y | 1 |
| Fernandez-Massip, H | 1 |
| Sosa-Gonzalez, I | 1 |
| Pérez-Esparza, R | 1 |
| Oñate-Cadena, N | 1 |
| Ramírez-Bermúdez, J | 1 |
| Espínola-Nadurille, M | 1 |
| Camilleri, L | 1 |
| Izadi Firouzabadi, L | 1 |
| Geer, K | 1 |
| Mead, P | 1 |
| Viloria Alebesque, A | 1 |
| Montes Castro, N | 1 |
| Arcos Sánchez, C | 1 |
| Vicente Gordo, D | 1 |
| Lucie, O | 1 |
| Nazir, F | 1 |
| Spilg, E | 1 |
| Lee, JH | 2 |
| Kim, K | 2 |
| Jo, YH | 2 |
| Lee, SH | 1 |
| Kang, C | 1 |
| Kim, J | 1 |
| Park, CJ | 1 |
| Kim, MA | 2 |
| Lee, MJ | 2 |
| Rhee, JE | 1 |
| Sendrowski, K | 1 |
| Sobaniec, W | 3 |
| Sobaniec, P | 1 |
| Sobaniec-Lotowska, ME | 4 |
| Belze, O | 1 |
| Remérand, F | 1 |
| Pujol, A | 1 |
| Fusciardi, J | 1 |
| Malyshev, AV | 1 |
| Razumkina, EV | 1 |
| Dubynin, VA | 1 |
| Myasoedov, NF | 1 |
| Amanat, S | 1 |
| Shahbaz, N | 1 |
| Hassan, Y | 1 |
| Dong, L | 1 |
| Zhang, M | 1 |
| Jia, M | 1 |
| Zhang, G | 1 |
| Qiu, L | 1 |
| Ji, M | 1 |
| Yang, J | 1 |
| Budhdeo, S | 1 |
| Marquette, M | 1 |
| Singh, D | 1 |
| Rajagopal, V | 1 |
| Larsen, EP | 1 |
| Ostergaard, JR | 1 |
| Melexopoulou, C | 1 |
| Marinaki, S | 1 |
| Darema, M | 1 |
| Skalioti, C | 1 |
| Efthimiou, A | 1 |
| Zavos, G | 1 |
| Boletis, JN | 1 |
| Rener-Primec, Z | 1 |
| Balkovec, V | 1 |
| Prakash, S | 2 |
| Harbo, T | 2 |
| Christensen, J | 2 |
| Hegazy, HG | 1 |
| Ali, EH | 1 |
| Elgoly, AH | 1 |
| Villalba Martínez, G | 1 |
| Fernández-Candil, JL | 1 |
| Vivanco-Hidalgo, RM | 1 |
| Pacreu Terradas, S | 1 |
| León Jorba, A | 1 |
| Arroyo Pérez, R | 1 |
| Zhu, D | 1 |
| Su, Z | 1 |
| Ye, S | 1 |
| Chen, X | 1 |
| Zhuge, G | 1 |
| Wu, Z | 1 |
| Al-sharefi, A | 1 |
| Bilous, R | 1 |
| Hwang, JE | 1 |
| Dawson, LP | 1 |
| Lee, SJ | 1 |
| Hollander, YS | 1 |
| Ciftci, S | 1 |
| Guler, A | 1 |
| Deveci, E | 1 |
| Celebisoy, N | 1 |
| Yuceyar, N | 1 |
| Gandolfo, F | 1 |
| Parodi, MN | 1 |
| Corsini, GP | 1 |
| Odetti, P | 1 |
| Serafini, G | 1 |
| Monacelli, F | 1 |
| Patel, N | 1 |
| Landry, KB | 1 |
| Fargason, RE | 1 |
| Birur, B | 1 |
| Pokorná, P | 1 |
| Hronová, K | 1 |
| Šíma, M | 1 |
| Slanař, O | 1 |
| Klement, P | 1 |
| van den Anker, JN | 1 |
| Tibboel, D | 1 |
| Tsai, MF | 1 |
| Chen, CY | 1 |
| LaRoche, SM | 1 |
| Shivdat-Nanhoe, R | 1 |
| Peura, L | 1 |
| Malmioja, K | 1 |
| Laine, K | 1 |
| Leppänen, J | 1 |
| Gynther, M | 1 |
| Isotalo, A | 1 |
| Rautio, J | 1 |
| Joardar, S | 1 |
| Chatterjee, R | 1 |
| Guha, G | 1 |
| Hasmi, MA | 1 |
| Noh, Y | 1 |
| Kim, DW | 1 |
| Chu, K | 1 |
| Lee, ST | 1 |
| Jung, KH | 1 |
| Moon, HJ | 1 |
| Lee, SK | 1 |
| Raspall-Chaure, M | 1 |
| Lainez, E | 1 |
| Toledo, M | 1 |
| Salas-Puig, J | 1 |
| Macaya-Ruiz, A | 1 |
| Roig-Quilis, M | 1 |
| Verrotti, A | 1 |
| Trotta, D | 1 |
| Morgese, G | 1 |
| Chiarelli, F | 1 |
| Yoshimura, K | 1 |
| Suzuki, H | 2 |
| Kimura, M | 2 |
| Lokrantz, CM | 1 |
| Eriksson, B | 1 |
| Rosén, I | 1 |
| Asztely, F | 1 |
| Reif, A | 1 |
| Leonhard, C | 1 |
| Mössner, R | 1 |
| Lesch, KP | 1 |
| Fallgatter, AJ | 1 |
| Kimmel, RJ | 1 |
| Irwin, SA | 1 |
| Meyer, JM | 1 |
| Cheung, E | 1 |
| Wong, V | 1 |
| Fung, CW | 1 |
| Rehman, A | 1 |
| Zafar, S | 1 |
| Thygesen, KS | 1 |
| Wolf, P | 1 |
| Gerstner, T | 1 |
| Buesing, D | 1 |
| Longin, E | 1 |
| Bendl, C | 1 |
| Wenzel, D | 1 |
| Scheid, B | 1 |
| Goetze, G | 1 |
| Macke, A | 1 |
| Lippert, G | 1 |
| Klostermann, W | 1 |
| Mayer, G | 1 |
| Augspach-Hofmann, R | 1 |
| Fitzek, S | 1 |
| Haensch, CA | 1 |
| Reuland, M | 1 |
| Koenig, SA | 1 |
| Zumsteg, D | 1 |
| Andrade, DM | 1 |
| Del Campo, JM | 1 |
| Wennberg, R | 1 |
| Morrison, PF | 1 |
| Sankar, R | 1 |
| Shields, WD | 1 |
| Zhu, HX | 1 |
| Cai, FC | 1 |
| Zhang, XP | 1 |
| Blum, W | 1 |
| Klisovic, RB | 1 |
| Hackanson, B | 1 |
| Liu, Z | 1 |
| Liu, S | 1 |
| Devine, H | 1 |
| Vukosavljevic, T | 1 |
| Huynh, L | 1 |
| Lozanski, G | 1 |
| Kefauver, C | 1 |
| Plass, C | 1 |
| Devine, SM | 1 |
| Heerema, NA | 1 |
| Murgo, A | 1 |
| Chan, KK | 1 |
| Grever, MR | 1 |
| Byrd, JC | 1 |
| Marcucci, G | 1 |
| Jedrzejczak, J | 1 |
| Kuncíková, M | 1 |
| Magureanu, S | 1 |
| Modjtahedi, B | 1 |
| Xiong, GL | 1 |
| Bauer, J | 1 |
| Young, P | 1 |
| Finn, BC | 1 |
| Alvarez, F | 1 |
| Bruetman, JE | 1 |
| Trimarchi, H | 1 |
| Coulter, DL | 1 |
| Allen, RJ | 1 |
| Zaccara, G | 1 |
| Boncinelli, L | 1 |
| Paganini, M | 1 |
| Campostrini, R | 1 |
| Arnetoli, G | 1 |
| Zappoli, R | 1 |
| Zaret, BS | 1 |
| Beckner, RR | 1 |
| Marini, AM | 1 |
| Wagle, W | 1 |
| Passarelli, C | 1 |
| Axelgaard, G | 1 |
| Seghieri, G | 1 |
| De Giorgio, LA | 1 |
| Innocenti, F | 1 |
| Pettiná, G | 1 |
| Zolfanelli, F | 1 |
| Apicella, P | 1 |
| Papazian, O | 1 |
| Cañizales, E | 1 |
| Alfonso, I | 1 |
| Archila, R | 1 |
| Duchowny, M | 1 |
| Aicardi, J | 1 |
| Averbuch-Heller, L | 1 |
| Ben-Hur, T | 1 |
| Reches, A | 1 |
| Katano, H | 1 |
| Nagai, H | 1 |
| Aihara, N | 1 |
| Yamashita, N | 1 |
| Kamiya, K | 1 |
| Ishikawa, T | 1 |
| Kanayama, M | 1 |
| Puri, AS | 1 |
| Sharma, BC | 1 |
| Khan, EM | 1 |
| Saraswat, VA | 1 |
| Chez, MG | 1 |
| Bourgeois, BF | 1 |
| Pippenger, CE | 1 |
| Knowles, WD | 1 |
| Mattei, A | 1 |
| Bernard, G | 1 |
| Plauchu, G | 2 |
| Paliard, P | 2 |
| Hennessy, MJ | 1 |
| Wiles, CM | 1 |
| Kuwahara, M | 1 |
| Shima, M | 1 |
| Nakai, H | 1 |
| Nishino, M | 1 |
| Fukuzumi, A | 1 |
| Yoshioka, A | 1 |
| Garaizar, C | 1 |
| Sousa, T | 1 |
| Lambarri, I | 1 |
| Martín, MA | 1 |
| Prats, JM | 1 |
| Papo, T | 1 |
| Biousse, V | 1 |
| Lehoang, P | 1 |
| Fardeau, C | 1 |
| N'Guyen, N | 1 |
| Huong, DL | 1 |
| Aumaitre, O | 1 |
| Bousser, MG | 1 |
| Godeau, P | 1 |
| Piette, JC | 1 |
| Guerrini, R | 1 |
| Belmonte, A | 1 |
| Canapicchi, R | 1 |
| Casalini, C | 1 |
| Perucca, E | 1 |
| Ichikawa, H | 1 |
| Amano, T | 1 |
| Kawabata, K | 1 |
| Kushiro, M | 1 |
| Wada, J | 1 |
| Nagake, Y | 1 |
| Makino, H | 1 |
| Göbel, R | 1 |
| Görtzen, A | 1 |
| Bräunig, P | 1 |
| Granström, ML | 1 |
| Gaily, E | 1 |
| Liukkonen, E | 1 |
| Beenen, LF | 1 |
| Lindeboom, J | 1 |
| Kasteleijn-Nolst Trenité, DG | 1 |
| Heimans, JJ | 1 |
| Snoek, FJ | 1 |
| Touw, DJ | 1 |
| Adèr, HJ | 1 |
| van Alphen, HA | 1 |
| Hamer, HM | 1 |
| Knake, S | 1 |
| Schomburg, U | 1 |
| Rosenow, F | 1 |
| Miyamoto, T | 1 |
| Miyamoto, M | 1 |
| Hirata, K | 1 |
| Katayama, S | 1 |
| Calvani, M | 1 |
| Parisi, P | 1 |
| Guaitolini, C | 1 |
| Parisi, G | 1 |
| Paolone, G | 1 |
| Dumont, O | 1 |
| Scoazec, JY | 1 |
| Cuber, JC | 1 |
| Guegen, L | 1 |
| Dumortier, J | 1 |
| Temkin, NR | 1 |
| Chen, WT | 1 |
| Yen, DJ | 1 |
| Yu, HY | 1 |
| Liao, KK | 1 |
| Vossler, DG | 1 |
| Wilensky, AJ | 1 |
| Cawthon, DF | 1 |
| Kraemer, DL | 1 |
| Ojemann, LM | 1 |
| Caylor, LM | 1 |
| Morgan, JD | 1 |
| Sobaniec-Lotowska, M | 1 |
| Augustynowicz, A | 1 |
| Chadwick, DW | 1 |
| Cumming, WJ | 1 |
| Livingstone, I | 1 |
| Cartlidge, NE | 1 |
| Fahn, S | 1 |
| Rowan, AJ | 1 |
| Binnie, CD | 1 |
| de Beer-Pawlikowski, NK | 1 |
| Goedhart, DM | 1 |
| Gutter, T | 1 |
| van der Geest, P | 1 |
| Meinardi, H | 1 |
| Meijer, JW | 1 |
| Yamamoto, K | 1 |
| Fukusako, T | 1 |
| Nogaki, H | 1 |
| Morimatsu, M | 1 |
| Murakami, K | 1 |
| Sugimoto, T | 1 |
| Nishida, N | 1 |
| Kobayashi, Y | 1 |
| Kuhara, T | 1 |
| Matsumoto, I | 1 |
| Khoo, SH | 1 |
| Leyland, MJ | 1 |
| Gentile, S | 1 |
| Buffa, C | 1 |
| Ravetti, C | 1 |
| Sacerdote, I | 1 |
| Smith, DB | 1 |
| Puri, V | 1 |
| Chowdhury, V | 1 |
| Gulati, P | 1 |
| Gram, L | 1 |
| Bentsen, KD | 1 |
| Gale, K | 1 |
| Cornford, EM | 1 |
| Oldendorf, WH | 1 |
| Wallace, SJ | 1 |
| Miyazaki, C | 1 |
| Matsuyama, K | 1 |
| Ichikawa, M | 1 |
| Goto, S | 1 |
| Gastaut, JL | 1 |
| Mege, JL | 1 |
| Tartara, A | 1 |
| Manni, R | 1 |
| Izumi, T | 1 |
| Utsumi, H | 1 |
| Osawa, M | 1 |
| Fukuyama, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I Study of Decitabine in Combination With Valproic Acid in Patients With Selected Hematologic Malignancies[NCT00079378] | Phase 1 | 84 participants (Actual) | Interventional | 2004-02-29 | Completed | ||
| Randomized Phase II Study on Decitabine Plus Carboplatin Versus Physician's Choice Chemotherapy in Recurrent, Platinum-resistant Ovarian Cancer.[NCT03467178] | Phase 2 | 119 participants (Anticipated) | Interventional | 2018-07-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
13 reviews available for valproic acid and Brain Disorders
| Article | Year |
|---|---|
A potential cause of adolescent onset Dyke-Davidoff-Masson syndrome: A case report.
Topics: Brain Diseases; Carbamazepine; China; Chronic Disease; Female; Humans; Intellectual Disability; Magn | 2019 |
Valproic acid-induced encephalopathy: A review of clinical features, risk factors, diagnosis, and treatment.
Topics: Anticonvulsants; Brain Diseases; Humans; Hyperammonemia; Risk Factors; Valproic Acid | 2021 |
Lesson of the month 1: Sodium valproate-induced encephalopathy.
Topics: Aged; Ammonia; Anticonvulsants; Brain Diseases; Carnitine; Consciousness Disorders; Epilepsy; Humans | 2018 |
Valproic acid-induced hyperammonemic encephalopathy in a full-term neonate: a brief review and case report.
Topics: Anticonvulsants; Brain Diseases; Humans; Hyperammonemia; Infant, Newborn; Seizures; Valproic Acid | 2017 |
Valproate-induced hyperammonemic encephalopathy.
Topics: Anticonvulsants; Brain Diseases; Humans; Hyperammonemia; Valproic Acid | 2002 |
[Organic manic disorder].
Topics: Bipolar Disorder; Brain Diseases; Carbamazepine; Clonazepam; Diagnostic and Statistical Manual of Me | 2003 |
[Organic bipolar disorder].
Topics: Bipolar Disorder; Brain Diseases; Carbamazepine; Humans; International Classification of Diseases; L | 2003 |
Susac syndrome.
Topics: Adult; Anti-Inflammatory Agents; Audiometry, Pure-Tone; Brain Diseases; Cyclophosphamide; Diagnosis, | 1998 |
Antiepileptogenesis and seizure prevention trials with antiepileptic drugs: meta-analysis of controlled trials.
Topics: Anticonvulsants; Brain Diseases; Brain Injuries; Carbamazepine; Controlled Clinical Trials as Topic; | 2001 |
Cognitive effects of antiepileptic drugs.
Topics: Anticonvulsants; Brain Diseases; Carbamazepine; Cognition; Drug Tolerance; Humans; Phenobarbital; Ph | 1991 |
Valproate: an updated review.
Topics: Abnormalities, Drug-Induced; Brain Diseases; Chemical and Drug Induced Liver Injury; Coma; Dyskinesi | 1985 |
Epilepsy and the blood-brain barrier.
Topics: Animals; Animals, Newborn; Anticonvulsants; Biological Transport; Biomechanical Phenomena; Blood Pro | 1986 |
Use of ethosuximide and valproate in the treatment of epilepsy.
Topics: Abnormalities, Drug-Induced; Brain Diseases; Drug Interactions; Epilepsies, Myoclonic; Epilepsies, P | 1986 |
4 trials available for valproic acid and Brain Disorders
| Article | Year |
|---|---|
Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Brain D | 2007 |
Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Brain D | 2007 |
Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Brain D | 2007 |
Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Brain D | 2007 |
An observational study of first-line valproate monotherapy in focal epilepsy.
Topics: Adolescent; Adult; Age Factors; Anticonvulsants; Brain Diseases; Child; Delayed-Action Preparations; | 2008 |
Treatment of infantile spasms: results of a population-based study with vigabatrin as the first drug for spasms.
Topics: 4-Aminobutyrate Transaminase; Adrenocorticotropic Hormone; Anticonvulsants; Brain Diseases; Child; C | 1999 |
Comparative double blind clinical trial of phenytoin and sodium valproate as anticonvulsant prophylaxis after craniotomy: efficacy, tolerability, and cognitive effects.
Topics: Adult; Aged; Brain Diseases; Cognition; Craniotomy; Double-Blind Method; Epilepsy; Female; Humans; M | 1999 |
109 other studies available for valproic acid and Brain Disorders
| Article | Year |
|---|---|
Non-hyperammonaemia valproate-induced encephalopathy: A case report.
Topics: Anticonvulsants; Brain Diseases; Epilepsy; Female; Humans; Hyperammonemia; Middle Aged; Valproic Aci | 2022 |
Valproate-Associated Hyperammonaemic Encephalopathy.
Topics: Anticonvulsants; Brain Diseases; Humans; Hyperammonemia; Male; Middle Aged; Neurotoxicity Syndromes; | 2022 |
Hyperammonaemic encephalopathy.
Topics: Brain Diseases; Humans; Neurotoxicity Syndromes; Valproic Acid | 2022 |
[A severe, reversible encephalopathy after prolonged use of valproic acid].
Topics: Aged; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Brain Diseases; Epilepsy; Female; Hum | 2023 |
Valproate-induced hyperammonemic encephalopathy treated by L-ornithine-L-aspartate: a case report.
Topics: Ammonia; Anticonvulsants; Brain Diseases; Humans; Male; Middle Aged; Valproic Acid | 2023 |
Valproate-related hyperammonemic encephalopathy with generalized suppression EEG: a case report.
Topics: Adult; Anticonvulsants; Brain Diseases; Electroencephalography; Epilepsy; Female; Humans; Hyperammon | 2023 |
Valproate overdose leading to hyperammonaemic encephalopathy.
Topics: Anticonvulsants; Brain Diseases; Humans; Hyperammonemia; Male; Neurotoxicity Syndromes; Valproic Aci | 2023 |
Acute Valproate-Induced Encephalopathy in Status Epilepticus: A Registry-Based Assessment.
Topics: Adult; Anticonvulsants; Brain Diseases; Humans; Hyperammonemia; Status Epilepticus; Valproic Acid | 2023 |
Cerebral and cerebellar pseudoatrophy associated with valproic acid. Report of three pediatric cases.
Topics: Anticonvulsants; Brain; Brain Diseases; Cerebellum; Child; Child, Preschool; Epilepsy; Humans; Neuro | 2023 |
Unusual case of sodium valproate-induced hyperammonaemia encephalopathy.
Topics: Bipolar Disorder; Brain Diseases; Humans; Hyperammonemia; Male; Middle Aged; Neoplasm Recurrence, Lo | 2023 |
Fulminant Onset of Valproate-Associated Hyperammonemic Encephalopathy.
Topics: Adult; Anticonvulsants; Brain Diseases; Humans; Hyperammonemia; Male; Valproic Acid | 2019 |
Valproate-induced hyperammonemic encephalopathy: a case report.
Topics: Antimanic Agents; Brain Diseases; Confusion; Female; Gait Ataxia; Humans; Hyperammonemia; Middle Age | 2020 |
Reversible Splenial Lesion Syndrome with Some Novel Causes and Clinical Manifestations.
Topics: Adult; Anticonvulsants; Brain Diseases; Carbamazepine; Causality; Corpus Callosum; Female; Headache; | 2020 |
Valproic acid and zonisamide induced hyperammonemic encephalopathy.
Topics: Adult; Anticonvulsants; Brain; Brain Diseases; Epilepsy; Humans; Hyperammonemia; Magnetic Resonance | 2020 |
Brain transcriptomics of nonhuman primates: A review.
Topics: Aging; Animals; Brain; Brain Diseases; Disease Models, Animal; Ethanol; Humans; Methamphetamine; Neu | 2021 |
Managing valproic acid toxicity-related hyperammonaemia: an unpredicted course.
Topics: Adult; Brain Diseases; Carnitine; Drug Overdose; Female; Humans; Hyperammonemia; Valproic Acid; Youn | 2021 |
Valproate-induced fatal acute hyperammonaemia-related encephalopathy in late-onset ornithine transcarbamylase deficiency.
Topics: Adult; Brain Diseases; Humans; Hyperammonemia; Male; Ornithine Carbamoyltransferase Deficiency Disea | 2021 |
Valproic-induced Hyperammonemic Encephalopathy Aggravated by Combined Use of Topiramate - A Case Report.
Topics: Anticonvulsants; Brain Diseases; Humans; Topiramate; Valproic Acid | 2021 |
SLC13A5-related epileptic encephalopathy successfully treated with valproate and acetazolamide.
Topics: Acetazolamide; Brain Diseases; Epilepsy, Generalized; Humans; Symporters; Valproic Acid | 2021 |
Burst Suppression Pattern on Electroencephalogram Secondary to Valproic Acid-Induced Hyperammonemic Encephalopathy.
Topics: Adolescent; Anticonvulsants; Autistic Disorder; Brain Diseases; Electroencephalography; Epilepsy; Fe | 2017 |
The damaged cortices and the uncontrolled Id: A case of post-measles hyper-sexuality.
Topics: Antipsychotic Agents; Brain; Brain Diseases; Child; Diagnosis, Differential; GABA Agents; Humans; Id | 2017 |
Two gaps too many, three clues too few? Do elevated osmolal and anion gaps with crystalluria always mean ethylene glycol poisoning?
Topics: Acid-Base Equilibrium; Acidosis; Anticonvulsants; Brain Diseases; Calcium Oxalate; Cognitive Dysfunc | 2017 |
[Treatment of encephalopathy by means of valproic acid with carglumic acid. Reply].
Topics: Anticonvulsants; Brain Diseases; Glutamates; Humans; Valproic Acid | 2018 |
[Treatment of encephalopathy by means of valproic acid with carglumic acid].
Topics: Anticonvulsants; Brain Diseases; Glutamates; Humans; Valproic Acid | 2018 |
Valproate-induced Hyperammonemic Encephalopathy Presenting as Catatonia.
Topics: Adult; Anticonvulsants; Brain Diseases; Catatonia; Epilepsy; Female; Humans; Hyperammonemia; Valproi | 2018 |
Severe hyperammonaemic encephalopathy resulting from the overlap between hepatic and valproate encephalopathy.
Topics: Alcoholism; Brain Diseases; Epilepsy; Humans; Hyperammonemia; Hypertension, Portal; Male; Middle Age | 2018 |
Non-convulsive status epilepticus secondary to valproate-induced hyperammonaemic encephalopathy.
Topics: Anticonvulsants; Brain Diseases; Humans; Neurotoxicity Syndromes; Status Epilepticus; Valproic Acid | 2020 |
A case of valproate-induced hyperammonaemic encephalopathy.
Topics: Aged; Anticonvulsants; Brain Diseases; Female; Humans; Hyperammonemia; Valproic Acid | 2013 |
Effect of valproic acid on survival and neurologic outcomes in an asphyxial cardiac arrest model of rats.
Topics: Animals; Asphyxia; Brain Diseases; Disease Models, Animal; Enzyme Inhibitors; Heart Arrest; Male; Ra | 2013 |
Ultrastructural study of hippocampal cortex neurons in an experimental model of valproate encephalopathy.
Topics: Animals; Brain Diseases; Cerebral Cortex; Cytoplasm; Disease Models, Animal; Hippocampus; Male; Neur | 2013 |
Hyperammonaemic encephalopathy and a flat electroencephalogram caused by valproic acid.
Topics: Adult; Anesthesia, General; Anticonvulsants; Brain Diseases; Craniocerebral Trauma; Electroencephalo | 2013 |
Semax corrects brain dysfunction caused by prenatal introduction of valproic acid.
Topics: Adrenocorticotropic Hormone; Animals; Animals, Newborn; Anticonvulsants; Brain Diseases; Female; Mal | 2013 |
Valproic acid induced hyperammonaemic encephalopathy.
Topics: Adolescent; Adult; Anticonvulsants; Brain Diseases; Child; Child, Preschool; Cohort Studies; Epileps | 2013 |
Class I histone deacetylase inhibitor valproic acid reverses cognitive deficits in a mouse model of septic encephalopathy.
Topics: Animals; Brain Diseases; Brain-Derived Neurotrophic Factor; Carbazoles; Cecum; Cognition Disorders; | 2013 |
Normoammonemic encephalopathy: solely valproate induced or multiple mechanisms?
Topics: Aged; Aggression; Anti-N-Methyl-D-Aspartate Receptor Encephalitis; Brain Diseases; Confusion; Delusi | 2014 |
Valproate-induced hyperammonemia in juvenile ceroid lipofuscinosis (Batten disease).
Topics: Adolescent; Anticonvulsants; Brain Diseases; Carnitine; Drug Therapy, Combination; Female; Humans; H | 2014 |
Valproate-induced hyperammonemic encephalopathy in a renal transplanted patient.
Topics: Adolescent; Anticonvulsants; Brain Diseases; Female; Humans; Hyperammonemia; Kidney Transplantation; | 2014 |
Valproate-related erythrodermia with reversible encephalopathy: a rare but serious adverse reaction, case report.
Topics: Anticonvulsants; Brain Diseases; Child, Preschool; Dermatitis, Exfoliative; Drug Eruptions; Humans; | 2014 |
[Valproate can induce reversible encephalopathy].
Topics: Aged; Anticonvulsants; Brain Diseases; Epilepsy; Female; Humans; Magnetic Resonance Imaging; Neuroto | 2014 |
Interplay between pro-inflammatory cytokines and brain oxidative stress biomarkers: evidence of parallels between butyl paraben intoxication and the valproic acid brain physiopathology in autism rat model.
Topics: Adenosine Monophosphate; Adenosine Triphosphate; Animals; Autistic Disorder; Biomarkers; Brain; Brai | 2015 |
Ammonia encephalopathy and awake craniotomy for brain language mapping: cause of failed awake craniotomy.
Topics: Anesthesia, General; Anesthesia, Local; Anticonvulsants; Aphasia; Benzodiazepines; Brain Diseases; B | 2015 |
[Clinical misdiagnosis analysis of valproate encephalopathy].
Topics: Anticonvulsants; Brain Diseases; Brain Edema; Brain Neoplasms; Diagnostic Errors; Epilepsy; Humans; | 2014 |
Reversible weakness and encephalopathy while on long-term valproate treatment due to carnitine deficiency.
Topics: Adult; Antimanic Agents; Brain Diseases; Cardiomyopathies; Carnitine; Female; Humans; Hyperammonemia | 2015 |
Effect of valproic acid combined with therapeutic hypothermia on neurologic outcome in asphyxial cardiac arrest model of rats.
Topics: Animals; Asphyxia; Brain Diseases; Combined Modality Therapy; Disease Models, Animal; Enzyme Inhibit | 2015 |
[Valproate can induce reversible encephalopathy].
Topics: Aged; Anticonvulsants; Brain Diseases; Epilepsy; Female; Humans; Magnetic Resonance Imaging; Neuroto | 2015 |
Valproate-induced hyperammonemic encephalopathy associated with urinary tract infection and urinary retention in the psychiatric setting.
Topics: Antimanic Agents; Bipolar Disorder; Brain Diseases; Humans; Hyperammonemia; Male; Middle Aged; Urina | 2016 |
A case with hyperammonemic encephalopathy triggered by single dose valproate.
Topics: Attention Deficit Disorder with Hyperactivity; Brain Diseases; Female; GABA Agents; Humans; Hyperamm | 2016 |
Valproate-induced encephalopathy in a comorbid elderly woman.
Topics: Anticonvulsants; Brain Diseases; Comorbidity; Female; Humans; Hyperammonemia; Lethargy; Middle Aged; | 2017 |
Reversible Encephalopathy due to Valproic Acid Induced Hyperammonemia in a Patient with Bipolar I Disorder: A Cautionary Report.
Topics: Antimanic Agents; Bipolar Disorder; Brain Diseases; Female; Humans; Hyperammonemia; Middle Aged; Val | 2017 |
Valproate-induced hyperammonemic encephalopathy treated by hemodialysis.
Topics: Adolescent; Anticonvulsants; Brain Diseases; Female; Humans; Hyperammonemia; Renal Dialysis; Valproi | 2008 |
Subacute encephalopathy and seizures in alcoholics (SESA) presenting with non-convulsive status epilepticus.
Topics: Acetamides; Alcohol Withdrawal Seizures; Alcoholism; Anticonvulsants; Brain Diseases; Confusion; Dif | 2011 |
Large amino acid transporter 1 (LAT1) prodrugs of valproic acid: new prodrug design ideas for central nervous system delivery.
Topics: Algorithms; Animals; Biological Transport; Blood-Brain Barrier; Brain; Brain Diseases; Central Nervo | 2011 |
Unilateral basal-ganglia involvement likely due to valproate-induced hyperammonemic encephalopathy.
Topics: Anticonvulsants; Basal Ganglia; Brain Diseases; Child, Preschool; Diffusion Magnetic Resonance Imagi | 2012 |
Topiramate increases the risk of valproic acid-induced encephalopathy.
Topics: Adult; Aged; Anticonvulsants; Brain Diseases; Drug Interactions; Drug Therapy, Combination; Electroe | 2013 |
[Reversible encephalopathy caused by valproic acid in an adolescent with idiopathic generalised epilepsy].
Topics: Adolescent; Anticonvulsants; Brain Diseases; Epilepsy, Generalized; Humans; Male; Valproic Acid | 2012 |
A case of nonconvulsive status epilepticus associated with focal cortical dysplasia.
Topics: Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Brain Diseases; Cerebral Cortex; Child; Child | 2003 |
Ultrastructure of astrocytes in the cortex of the hippocampal gyrus and in the neocortex of the temporal lobe in experimental valproate encephalopathy and after valproate withdrawal.
Topics: Animals; Anticonvulsants; Astrocytes; Behavior, Animal; Brain Diseases; Male; Microscopy, Electron; | 2003 |
Hyperammonemic encephalopathy induced by a combination of valproate and pivmecillinam.
Topics: Aged; Amdinocillin Pivoxil; Anti-Bacterial Agents; Anticonvulsants; Brain Diseases; Female; Humans; | 2004 |
Encephalopathy and myoclonus triggered by valproic acid.
Topics: Adult; Antimanic Agents; Brain Diseases; Electroencephalography; Humans; Male; Myoclonus; Valproic A | 2004 |
Valproic acid-associated hyperammonemic encephalopathy: a case report from the psychiatric setting.
Topics: Antimanic Agents; Bipolar Disorder; Brain Diseases; Confusion; Female; Humans; Hyperammonemia; Middl | 2005 |
Topiramate-valproate-induced hyperammonemic encephalopathy syndrome: case report.
Topics: Adolescent; Anticonvulsants; Brain Diseases; Chromosome Inversion; Chromosomes, Human, Pair 15; Drug | 2005 |
Valproate-induced encephalopathy.
Topics: Aged; Anticonvulsants; Brain Diseases; Electroencephalography; Female; Humans; Valproic Acid | 2005 |
[Valproate-caused encephalopathy].
Topics: Aged; Anticonvulsants; Brain Diseases; Humans; Male; Mental Status Schedule; Neurotoxicity Syndromes | 2005 |
Valproic acid induced encephalopathy--19 new cases in Germany from 1994 to 2003--a side effect associated to VPA-therapy not only in young children.
Topics: Adolescent; Aged; Anticonvulsants; Brain Diseases; Child, Preschool; Female; Humans; Hyperammonemia; | 2006 |
Parietal lobe source localization and sensitivity to hyperventilation in a patient with subclinical rhythmic electrographic discharges of adults (SREDA).
Topics: Aged; Anticonvulsants; Brain Diseases; Electroencephalography; Humans; Hyperventilation; Magnetic Re | 2006 |
Valproate-induced chorea and encephalopathy in atypical nonketotic hyperglycinemia.
Topics: Anticonvulsants; Brain Diseases; Child; Chorea; Female; Humans; Hyperglycinemia, Nonketotic; Valproi | 2006 |
[Experimental study on the possibility of brain damage induced by chronic treatment with phenobarbital, clonazepam, valproic acid and topiramate in immature rats].
Topics: Age Factors; Animals; Anticonvulsants; Apoptosis; bcl-2-Associated X Protein; Brain; Brain Diseases; | 2007 |
Hyperammonemia and valproic acid-induced encephalopathy.
Topics: Brain Diseases; Humans; Hyperammonemia; Protein Binding; Valproic Acid | 2007 |
Encephalopathy induced by levetiracetam added to valproate.
Topics: Adult; Anticonvulsants; Brain Diseases; Electroencephalography; Epilepsy; Humans; Levetiracetam; Mal | 2008 |
[Valproate-associated hyperammonemic encephalopathy. Report of one case].
Topics: Aged; Anticonvulsants; Brain Diseases; Female; Humans; Hyperammonemia; Valproic Acid | 2007 |
Secondary hyperammonaemia: a possible mechanism for valproate encephalopathy.
Topics: Ammonia; Brain; Brain Diseases; Child, Preschool; Epilepsy; Female; Humans; Propionates; Valproic Ac | 1980 |
Treatment of epileptic patients with valproic acid does not modify plasma and urine short-chain-fatty acids.
Topics: Adolescent; Adult; Ammonia; Brain Diseases; Butyrates; Epilepsy; Fatty Acids; Female; Hemiterpenes; | 1983 |
Sodium valproate-induced hyperammonemia without clinical hepatic dysfunction.
Topics: Adult; Ammonia; Brain Diseases; Dose-Response Relationship, Drug; Drug Therapy, Combination; Electro | 1982 |
[Liver involvement and encephalopathy in a child during sodium valproate therapy].
Topics: Brain Diseases; Chemical and Drug Induced Liver Injury; Child, Preschool; Female; Humans; Valproic A | 1982 |
[Description of a case of a syndrome similar to Reye's syndrome in a male adult undergoing treatment with valproic acid and phenobarbital].
Topics: Adult; Brain Diseases; Coma; Epilepsy, Tonic-Clonic; Fever; Humans; Male; Muscle Rigidity; Phenobarb | 1982 |
Reversible dementia and apparent brain atrophy during valproate therapy.
Topics: Atrophy; Brain Diseases; Child; Child, Preschool; Dementia; Epilepsy; Female; Humans; Magnetic Reson | 1995 |
Valproate encephalopathy and hypocarnitinaemia in diabetic patients.
Topics: Adolescent; Adult; Brain Diseases; Carnitine; Diabetes Mellitus, Type 1; Electroencephalography; Epi | 1994 |
West syndrome associated with porencephaly.
Topics: Adrenocorticotropic Hormone; Brain Diseases; Child, Preschool; Clonazepam; Comorbidity; Cysts; Elect | 1994 |
Fatal fulminant hepatic failure due to sodium valproate in an adolescent.
Topics: Adolescent; Brain Diseases; Drug Therapy, Combination; Fatal Outcome; Hepatic Encephalopathy; Humans | 1994 |
Pharmacodynamic interactions between phenytoin and valproate: individual and combined antiepileptic and neurotoxic actions in mice.
Topics: Animals; Brain; Brain Diseases; Drug Interactions; Drug Synergism; Electroshock; Epilepsy; Female; M | 1994 |
[Encephalopathy associated with hyperammonemia in an alcoholic patient treated with sodium valproate].
Topics: Ammonia; Brain Diseases; Drug Therapy, Combination; Humans; Male; Middle Aged; Phenobarbital; Psycho | 1993 |
Lamotrigine encephalopathy.
Topics: Anticonvulsants; Astrocytoma; Brain Diseases; Brain Neoplasms; Drug Interactions; Female; Frontal Lo | 1996 |
A case of West syndrome with atypical massive gray matter heterotopia that is well controlled by ACTH therapy.
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Brain; Brain Diseases; Choristoma; Clonazepam; Drug Th | 1996 |
Morphological features of encephalopathy after chronic administration of the antiepileptic drug valproate to rats. A transmission electron microscopic study of capillaries in the cerebellar cortex.
Topics: Animals; Brain Diseases; Capillaries; Cerebellum; Dose-Response Relationship, Drug; Drug Administrat | 1996 |
[Clinical workload at the outpatient neuropediatric clinic].
Topics: Adolescent; Ambulatory Care; Brain Diseases; Child; Child, Preschool; Electroencephalography; Female | 1997 |
Reversible pseudoatrophy of the brain and mental deterioration associated with valproate treatment.
Topics: Atrophy; Brain; Brain Diseases; Child; Cognition Disorders; Diagnosis, Differential; Electroencephal | 1998 |
Fatal hyperammonemia in a patient with systemic lupus erythematosus.
Topics: Adult; Ammonia; Anticonvulsants; Brain Diseases; Fatal Outcome; Female; Humans; Kidney Failure, Chro | 1998 |
[Encephalopathies caused by valproate].
Topics: Adult; Ammonia; Anticonvulsants; Brain Diseases; Drug Interactions; Epilepsy; Humans; Middle Aged; V | 1999 |
Valproate-induced hyperammonemic encephalopathy in the presence of topiramate.
Topics: Adult; Ammonia; Anticonvulsants; Brain Diseases; Drug Therapy, Combination; Electroencephalography; | 2000 |
[A case report of valproate encephalopathy].
Topics: Adult; Ammonia; Anticonvulsants; Biomarkers; Brain; Brain Diseases; Carnitine; Epilepsy; Female; Hum | 1999 |
Latent coeliac disease in a child with epilepsy, cerebral calcifications, drug-induced systemic lupus erythematosus and intestinal folic acid malabsorption associated with impairment of folic acid transport across the blood-brain barrier.
Topics: Adolescent; Anticonvulsants; Biological Transport; Blood-Brain Barrier; Brain; Brain Diseases; Calci | 2001 |
[Encephalopathy induced by ingestion of ammonium during valproate therapy].
Topics: Brain Diseases; Diet; Drug Interactions; Female; Humans; Hyperammonemia; Middle Aged; Quaternary Amm | 2001 |
Valproate-induced encephalopathy.
Topics: Ammonia; Anticonvulsants; Brain Diseases; Electroencephalography; Female; Humans; Middle Aged; Valpr | 2001 |
Ultrastructure of Purkinje cell perikarya and their dendritic processes in the rat cerebellar cortex in experimental encephalopathy induced by chronic application of valproate.
Topics: Animals; Anticonvulsants; Brain Diseases; Cerebellar Cortex; Dendrites; Drug Administration Schedule | 2001 |
Serum and CSF glutamine levels in valproate-related hyperammonemic encephalopathy.
Topics: Adolescent; Adult; Ammonia; Anticonvulsants; Brain; Brain Diseases; Electroencephalography; Female; | 2002 |
Morphometric analysis of the cerebellar cortex capillaries in the course of experimental valproate encephalopathy and after chronic exposure to sodium valproate using transmission electron microscopy.
Topics: Animals; Anticonvulsants; Brain Diseases; Capillaries; Cerebellar Cortex; Cerebrovascular Circulatio | 2001 |
Acute intoxication with sodium valproate.
Topics: Acute Disease; Adolescent; Adult; Brain Diseases; Epilepsy; Female; Humans; Male; Valproic Acid | 1979 |
Posthypoxic action myoclonus: review of the literature and report of two new cases with response to valproate and estrogen.
Topics: Adult; Brain Diseases; Estrogens, Conjugated (USP); Female; Humans; Hypoxia; Hypoxia, Brain; Male; M | 1979 |
Sodium valproate: serial monitoring of EEG and serum levels.
Topics: Adolescent; Adult; Brain Diseases; Electroencephalography; Female; Humans; Middle Aged; Seizures; Va | 1979 |
[Multiple system atrophy with macro square wave jerks and pendular nystagmus].
Topics: Atrophy; Baclofen; Brain Diseases; Diazepam; Electrooculography; Eye Movements; Female; Humans; Midd | 1992 |
Abnormal metabolism of carnitine and valproate in a case of acute encephalopathy during chronic valproate therapy.
Topics: Brain Diseases; Carnitine; Cerebral Palsy; Child; Chronic Disease; Female; Gas Chromatography-Mass S | 1992 |
Cerebral edema following acute sodium valproate overdose.
Topics: Adult; Brain Diseases; Drug Overdose; Edema; Humans; Hypocalcemia; Kidney; Liver; Male; Valproic Aci | 1992 |
State of stupor from valproic acid during chronic treatment: case report.
Topics: Adult; Brain Diseases; Carbamazepine; Clonazepam; Electroencephalography; Epilepsies, Myoclonic; Fem | 1991 |
Myoclonus: a manifestation of neurocysticercosis.
Topics: Brain Diseases; Child; Cysticercosis; Female; Humans; Myoclonus; Praziquantel; Valproic Acid | 1991 |
Role of the substantia nigra in GABA-mediated anticonvulsant actions.
Topics: Aminocaproates; Aminooxyacetic Acid; Animals; Anticonvulsants; Brain; Brain Diseases; Denervation; D | 1986 |
Effect of sodium valproate (VPA) on cerebral amino acids: mechanism of gamma-aminobutyric acid (GABA) elevation and possible causal relation of VPA-induced encephalopathy and glutamine level.
Topics: Amino Acids; Animals; Brain Chemistry; Brain Diseases; gamma-Aminobutyric Acid; Glutamine; Male; Mic | 1988 |
[Encephalopathy with asterixis induced by sodium valproate. Role of hyperammonemia without hepatic insufficiency].
Topics: Ammonia; Brain Diseases; Humans; Male; Middle Aged; Movement Disorders; Valproic Acid | 1985 |
Sodium valproate "encephalopathy": report of three cases with generalised epilepsy.
Topics: Adult; Arousal; Brain Diseases; Child; Confusion; Electroencephalography; Epilepsy; Female; Humans; | 1985 |
[A clinico-biochemical study of acute encephalopathy in patients treated with Ca-hopantenate].
Topics: Acute Disease; Adolescent; Adult; Age Factors; Blood Chemical Analysis; Brain Diseases; Child; Child | 1985 |